Mobilized Leukopaks®, G-CSF, Fresh
Human mobilized peripheral blood Leukopaks provide a rich source of hematopoietic stem cells as compared to traditional Leukopaks. This allows researchers greater reproducibility of experiments from a single donor (minimize donor-to-donor variation), increase in scalability of experiments from a single product, and a decrease in same cell variability by obtaining high yields of specific cell types.
Mobilized Leukopaks are collected from healthy IRB consented donors that are injected with a combination of 10µg/kg/day of Granulocyte-Colony Stimulating Factor (G-CSF), which stimulates the bone marrow to produce hematopoietic stem cells and mobilizes them into the bloodstream, prior to the first day of collection. CD34+ hematopoietic stem cells account for 1-2% of the total nucleated cells (TNCs). Mobilized mononuclear cells are collected by a trained technician using the Spectra Optia® Apheresis System one and two days post injection. After collection, mobilized Leukopaks are checked by flow analysis to verify the percentage of granulocytes, mononuclear cells, CD34+ cells, and cell viability.
• 2x10e10 TNCs/1 bag
• Enriched MNCs
• 1-2% CD34+ cells
• Low hematocrit
• Low granulocytes
Cells were obtained using Institutional Review Board (IRB) approved consent forms and protocols.
We work closely with our customers to provide them with the product they need. For a custom order, please call and speak to one of our sales specialists at 530-303-3828.
|Cell and Tissue Source||Peripheral Blood|
|Cell Type||Mononuclear Cells|
|Donor Attributes||HIV-, HepB-, HepC-|
|Viability||≥90% by Flow Cytometry|
|Size||20 billion TNCs/bag|
|Injections||10μg/kg/day of G-CSF|
Product Information Sheet
Certificate of Analysis
Figure 1. Representative flow panel of fresh G-CSF mobilized leukopak. Enriched MNC population with low granulocytes (20.76%), high viability (97.65%), and high percentage of CD34+ cells (1.68%).